Loading...
A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia
Landoni, Giovanni Piemonti, Lorenzo Monforte, Antonella d'Arminio Grossi, Paolo Zangrillo, Alberto Allegretti, Marcello Goisis, Giovanni Gavioli, Elizabeth M. Patel, Neal
Landoni, Giovanni
Piemonti, Lorenzo
Monforte, Antonella d'Arminio
Grossi, Paolo
Zangrillo, Alberto
Allegretti, Marcello
Goisis, Giovanni
Gavioli, Elizabeth M.
Patel, Neal
Citations
Altmetric:
Genre
Journal article
Date
2022-05-26
Advisor
Committee member
Department
Biology
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
https://doi.org/10.1007/s40121-022-00644-6
Abstract
Acute lung injury and acute respiratory distress syndrome are common complications in patients with coronavirus disease 2019 (COVID-19). Poor outcomes in patients with COVID-19 are associated with cytokine release syndrome. Binding of interleukin-8 (CXCL8/IL-8) to its chemokine receptors, CXCR1/2, may mediate this inflammatory process. The aim of this clinical trial was to determine if CXCR1/2 blockade with reparixin can improve clinical outcomes in hospitalized patients with severe COVID-19 pneumonia. The dose and safety of reparixin have been investigated in clinical trials of patients with metastatic breast cancer.
Description
Citation
Landoni, G., Piemonti, L., Monforte, A.d. et al. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia. Infect Dis Ther 11, 1559–1574 (2022). https://doi.org/10.1007/s40121-022-00644-6
Citation to related work
Springer
Has part
Infectious Diseases and Therapy, Vol. 11
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu